Xeljanz (tofacitinib) vs Jyseleca (filgotinib)

Xeljanz (tofacitinib) and Jyseleca (filgotinib) are both oral medications classified as Janus kinase (JAK) inhibitors, used to treat conditions like rheumatoid arthritis by modulating the immune system. Xeljanz has been approved for use in several conditions including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, and has a longer track record in clinical use, which provides a more extensive safety and efficacy profile. Jyseleca, on the other hand, is a newer medication with a potentially more selective action on the JAK1 pathway, which may offer different safety and efficacy outcomes, although its long-term effects are less well-known compared to Xeljanz; the choice between the two should be based on individual patient health profiles, physician recommendation, and regulatory approvals for the specific condition being treated.

Difference between Xeljanz and Jyseleca

Metric	Xeljanz (tofacitinib)	Jyseleca (filgotinib)
Generic name	Tofacitinib	Filgotinib
Indications	Rheumatoid arthritis, Psoriatic arthritis, Ulcerative colitis	Rheumatoid arthritis, Psoriatic arthritis
Mechanism of action	JAK inhibitor	JAK1 inhibitor
Brand names	Xeljanz, Xeljanz XR	Jyseleca
Administrative route	Oral	Oral
Side effects	Upper respiratory tract infections, Headache, Diarrhea, Nasopharyngitis	Nausea, Upper respiratory tract infections, Urinary tract infections, Dizziness
Contraindications	Severe liver impairment, Active serious infections, History of certain malignancies	Severe liver impairment, Active serious infections
Drug class	JAK inhibitor	JAK inhibitor
Manufacturer	Pfizer	Gilead Sciences, Galapagos NV

Efficacy

Xeljanz (Tofacitinib) Efficacy in Rheumatoid Arthritis

Xeljanz (tofacitinib) is an oral medication that belongs to a class of drugs known as Janus kinase (JAK) inhibitors. It is approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. The efficacy of Xeljanz in treating RA has been demonstrated in several clinical trials. These trials have shown that tofacitinib can reduce signs and symptoms, improve physical function, and inhibit the progression of structural damage in patients with RA.

In pivotal phase 3 trials, Xeljanz, administered as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs (DMARDs), has shown a rapid onset of action, often within the first two weeks of treatment. Patients treated with Xeljanz experienced significant improvements in the American College of Rheumatology (ACR) criteria, which measure the reduction of RA symptoms, compared to placebo. Furthermore, Xeljanz has been associated with a reduction in the rate of joint damage progression as detected by X-ray, which is a critical aspect of managing RA over the long term.

Jyseleca (Filgotinib) Efficacy in Rheumatoid Arthritis

Jyseleca (filgotinib) is another JAK inhibitor that is used for the treatment of adults with moderate to severe rheumatoid arthritis. It is indicated for patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). Clinical trials have shown that filgotinib is effective in reducing the signs and symptoms of RA, improving physical function, and inhibiting the progression of structural joint damage.

Key clinical studies have demonstrated that patients taking filgotinib achieved significant improvements in ACR response criteria, as well as in the Disease Activity Score (DAS28), which is another measure of disease activity in RA. Filgotinib has been shown to be effective both as a monotherapy and in combination with methotrexate or other conventional DMARDs. The drug has a favorable efficacy profile, with a consistent response across various patient populations, including those with different levels of disease activity and prior treatment histories.

Regulatory Agency Approvals

Xeljanz

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Jyseleca

European Medical Agency (EMA), European Union
Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Xeljanz or Jyseleca today

If Xeljanz or Jyseleca are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Xeljanz

Buy Jyseleca

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: